Anti-CD19 therapy refers to treatments that target the CD19 protein on B cells, most commonly in B-cell cancers and some autoimmune diseases.
CD19 therapy targets the CD19 protein found on healthy and malignant B-cells .
It treats B-cell leukemias, lymphomas, and severe autoimmune diseases (like lupus and scleroderma) using CD19 Monoclonal Antibodies (e.g., tafasitamab), Antibody-Drug Conjugates (e.g., loncastuximab), Bispecific Antibodies, or CAR T-cell therapy .
It includes several different drug classes, such as monoclonal antibodies, antibody-drug conjugates, and CAR-T cell therapies.
Tafasitamab is an anti-CD19 monoclonal antibody used with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.
Loncastuximab tesirine an anti-CD19 antibody-drug conjugate used in relapsed/refractory DLBCL.
CD19 CAR-T therapies engineered T-cell treatments that attack CD19-positive B cells and have expanded the field of B-cell malignancy care.
Emerging in vivo CD19-directed approaches: newer CD19-directed CAR-T strategies are still being developed.
These therapies are mainly used for **B-cell malignancies** because CD19 is broadly expressed on healthy and malignant B cells.
They are especially relevant when disease is relapsed or refractory after prior lines of therapy, including situations where transplant or CAR-T options are limited.
Targeting CD19 can affect normal B cells too, so clinicians monitor for **B-cell depletion**, infection risk, and other toxicities.
Prior CD19-directed therapy may influence later CD19-targeted CAR-T treatment decisions.
CAR T-cell Therapy: A patient’s own T-cells are genetically engineered to specifically hunt down cells expressing CD19.
Monoclonal Antibodies & Conjugates: These drugs bind to CD19, triggering the destruction of targeted cells or delivering chemotherapy directly to the B-cells .
Bispecific T-cell Engagers (BiTEs): These treatments act as a bridge, pulling the patient’s own immune T-cells directly to the CD19+ cancer cells.
Common IndicationsOncology: Relapsed or refractory non-Hodgkin lymphomas (like DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL).
Investigated for refractory, systemic diseases where pathogenic B-cells must be cleared.
Primary Side EffectsBecause CD19 therapies wipe out healthy B-cells alongside malignant ones, they can cause long-term side effects increased risk of infection, hypogammaglobulinemia (low antibodies), and unique immediate risks like Cytokine Release Syndrome (CRS) and neurotoxicity.